Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of PI3K/AKT/mTor Pathway Inhibitors for Breast Cancermarket, defines the market attractiveness level of PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer industry, describes the types of PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer market, the applications of major players and the market size, and deeply analyzes the current situation of the global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer market and the development prospects and opportunities of PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer market in Chapter 13.
By Player:
Novartis
Pfizer
Dr Reddy’s Laboratories
Alkem Laboratories
Glenmark Pharmaceuticals
Cipla
Biocon Pharma
Accord Healthcare
Gland Pharma
Panacea Biotec
Intas Pharmaceuticals
Natco Pharma
By Type:
Temsirolimus
Everolimus
By End-User:
Hospital
Clinic
Drug Center
Other
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Analysis and Outlook to 2022
-
7.1 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption (2017-2022)
-
7.2 United States PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption (2017-2022)
-
7.3 Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption (2017-2022)
-
7.4 China PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption (2017-2022)
-
7.5 Japan PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption (2017-2022)
-
7.6 India PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption (2017-2022)
-
7.7 South Korea PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption (2017-2022)
8 Region and Country-wise PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Analysis and Outlook to 2028
-
8.1 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption Forecast (2022-2028)
-
8.2 United States PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption Forecast (2022-2028)
-
8.3 Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption Forecast (2022-2028)
-
8.4 China PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption Forecast (2022-2028)
-
8.5 Japan PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption Forecast (2022-2028)
-
8.6 India PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption Forecast (2022-2028)
-
8.7 South Korea PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption Forecast (2022-2028)
9 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Outlook by Types and Applications to 2022
-
9.1 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Temsirolimus Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Everolimus Consumption and Growth Rate (2017-2022)
-
9.2 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Drug Center Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Other Consumption and Growth Rate (2017-2022)
10 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Outlook by Types and Applications to 2028
-
10.1 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Temsirolimus Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Everolimus Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Drug Center Consumption Forecast and Growth Rate (2022-2028)
-
10.2.4 Global Other Consumption Forecast and Growth Rate (2022-2028)
11 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Import and Export Analysis (Top 5 Countries)
-
11.1 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Competitive Analysis
-
14.1 Novartis
-
14.1.1 Novartis Company Details
-
14.1.2 Novartis PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Novartis PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
-
14.2 Pfizer
-
14.2.1 Pfizer Company Details
-
14.2.2 Pfizer PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Pfizer PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
-
14.3 Dr Reddy’s Laboratories
-
14.3.1 Dr Reddy’s Laboratories Company Details
-
14.3.2 Dr Reddy’s Laboratories PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Dr Reddy’s Laboratories PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
-
14.4 Alkem Laboratories
-
14.4.1 Alkem Laboratories Company Details
-
14.4.2 Alkem Laboratories PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Alkem Laboratories PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
-
14.5 Glenmark Pharmaceuticals
-
14.5.1 Glenmark Pharmaceuticals Company Details
-
14.5.2 Glenmark Pharmaceuticals PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Glenmark Pharmaceuticals PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
-
14.6 Cipla
-
14.6.1 Cipla Company Details
-
14.6.2 Cipla PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Cipla PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
-
14.7 Biocon Pharma
-
14.7.1 Biocon Pharma Company Details
-
14.7.2 Biocon Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Biocon Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
-
14.8 Accord Healthcare
-
14.8.1 Accord Healthcare Company Details
-
14.8.2 Accord Healthcare PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 Accord Healthcare PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
-
14.9 Gland Pharma
-
14.9.1 Gland Pharma Company Details
-
14.9.2 Gland Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
14.9.3 Gland Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
-
14.10 Panacea Biotec
-
14.10.1 Panacea Biotec Company Details
-
14.10.2 Panacea Biotec PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
14.10.3 Panacea Biotec PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
-
14.11 Intas Pharmaceuticals
-
14.11.1 Intas Pharmaceuticals Company Details
-
14.11.2 Intas Pharmaceuticals PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
14.11.3 Intas Pharmaceuticals PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
-
14.12 Natco Pharma
-
14.12.1 Natco Pharma Company Details
-
14.12.2 Natco Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
14.12.3 Natco Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer
-
Figure PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Picture
-
Table Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption by Country (2017-2022)
-
Figure United States PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Table Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure China PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Japan PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure India PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure South Korea PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption Forecast by Country (2022-2028)
-
Figure United States PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure China PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure India PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Temsirolimus Consumption and Growth Rate (2017-2022)
-
Figure Global Everolimus Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Consumption and Growth Rate (2017-2022)
-
Figure Global Clinic Consumption and Growth Rate (2017-2022)
-
Figure Global Drug Center Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global Temsirolimus Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Everolimus Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Drug Center Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Table Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Import by Region (Top 5 Countries) (2017-2028)
-
Table Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Export by Region (Top 5 Countries) (2017-2028)
-
Table Novartis (Foundation Year, Company Profile and etc.)
-
Table Novartis PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
-
Table Pfizer (Foundation Year, Company Profile and etc.)
-
Table Pfizer PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
-
Table Dr Reddy’s Laboratories (Foundation Year, Company Profile and etc.)
-
Table Dr Reddy’s Laboratories PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Dr Reddy’s Laboratories PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
-
Table Alkem Laboratories (Foundation Year, Company Profile and etc.)
-
Table Alkem Laboratories PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Alkem Laboratories PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
-
Table Glenmark Pharmaceuticals (Foundation Year, Company Profile and etc.)
-
Table Glenmark Pharmaceuticals PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Glenmark Pharmaceuticals PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
-
Table Cipla (Foundation Year, Company Profile and etc.)
-
Table Cipla PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cipla PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
-
Table Biocon Pharma (Foundation Year, Company Profile and etc.)
-
Table Biocon Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Biocon Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
-
Table Accord Healthcare (Foundation Year, Company Profile and etc.)
-
Table Accord Healthcare PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Accord Healthcare PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
-
Table Gland Pharma (Foundation Year, Company Profile and etc.)
-
Table Gland Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Gland Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
-
Table Panacea Biotec (Foundation Year, Company Profile and etc.)
-
Table Panacea Biotec PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Panacea Biotec PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
-
Table Intas Pharmaceuticals (Foundation Year, Company Profile and etc.)
-
Table Intas Pharmaceuticals PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Intas Pharmaceuticals PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
-
Table Natco Pharma (Foundation Year, Company Profile and etc.)
-
Table Natco Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales, Price, Value and Gross Profit (2017-2022)
-
Table Natco Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product and Service
-
